A short-term Medicare program is offering eligible Part D beneficiaries a flat $50 monthly copay for Wegovy and two other weight-loss drugs, a fraction of the $199 to $699 a month those medications can cost without the discount. The Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge on July 1, 2026, and recently extended it to run through the end of 2027. For a program that has never covered weight-loss drugs before, the shift marks a genuine change, though it comes with eligibility rules and a hard expiration date.
Who Qualifies for the $50 Copay
According to Medicare’s own fact sheet on the program, a beneficiary must be enrolled in Part D drug coverage, not already receiving a GLP-1 drug through that plan for another qualifying condition, and at least 18 years old with a body mass index of 35 or higher, or 30 or higher paired with heart failure, high blood pressure, or chronic kidney disease, or 27 or higher paired with prediabetes or a history of heart attack or stroke.
CMS’s program page notes that beneficiaries already using a GLP-1 for type 2 diabetes, moderate-to-severe sleep apnea, or a liver condition called MASH are not eligible for the Bridge program, since Part D already covers those uses directly. The $50 copay applies specifically to weight-loss use, and it does not count toward a beneficiary’s Part D deductible or the program’s separate annual out-of-pocket cap.
The program covers three specific products: the injectable and tablet forms of Wegovy, the KwikPen version of Zepbound, and a newer pill called Foundayo. Single-dose Zepbound pens and vials are excluded from the discount entirely, so the specific product a pharmacy dispenses matters as much as the underlying drug name. Beneficiaries who already started one of these drugs before the Bridge program existed can still qualify, but their prescriber has to confirm in the paperwork that the original prescription met the current criteria at the time treatment began, even if the beneficiary has since lost enough weight to fall under the BMI threshold.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
How the Program Actually Works at the Pharmacy
Reporting on the program’s rollout described an unusual approval process: rather than going through a beneficiary’s regular Part D plan, a prescriber submits the prescription and a prior authorization request to a central system run by a CMS contractor, and once approved, the beneficiary simply pays the flat $50 at the pharmacy counter. Part D plans are not required to opt into the Bridge program for their members to use it, and doctors do not need to be enrolled as Medicare providers to submit the paperwork.
That structure is why the $50 copay does not move the needle on a beneficiary’s broader Part D spending. Because the Bridge program operates outside the standard Part D payment and coverage flow entirely, none of the money paid toward it applies to the deductible or the annual ceiling that governs every other covered prescription a beneficiary fills that year.
The predictability is deliberate. Unlike a standard coinsurance arrangement, where a beneficiary’s share of the cost rises alongside the dose, the $50 Bridge copay stays flat even as a prescriber increases the dosage over time, which matters given that most people on these medications eventually need a higher dose to maintain results. Refills do not require a new approval from Medicare either, as long as the beneficiary stays on the same drug, which keeps the process simpler than a typical prior-authorization renewal.
Why the Program Has a 2027 Expiration Date
The Bridge program was originally designed to last just six months, created as a stopgap ahead of a larger, longer-term Medicare weight-loss drug model that was supposed to begin in 2027 and shift more of the cost onto insurers rather than the government. Not enough insurance companies agreed to take part in that longer-term model by its spring deadline, so CMS extended the Bridge program by an additional year instead, pushing the expiration to December 31, 2027.
That extension leaves the future genuinely uncertain for beneficiaries who start the medication now. Health policy researchers have noted that the government has not disclosed cost estimates for the program, and that continuing it is likely to run into the billions of dollars annually, which puts pressure on whether Washington extends it again once the current window closes.
For a beneficiary living on a fixed Social Security income, a $50 monthly copay is still real money, particularly since research on these drugs shows many people regain lost weight once they stop taking them. But set against retail prices that can top $600 a month without any discount, the Bridge program is, for now, the most affordable route onto a GLP-1 medication that Medicare has ever offered — with a clock already running toward the program’s last day.
This article was produced with the assistance of AI and reviewed by The Money Overview editorial team before publication.
More Financial Reading
